Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus Story 2 Small-Cap Biotechs That Could Reward Patient InvestorsBy Chris Markoch. Posted: 12/12/2025. 
Quick Look - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most, if not all, of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. It also means these companies have negative earnings (not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. If you've built substantial wealth, capital gains taxes may quietly erode far more of your investment returns than you realize.
The good news? The tax code offers legitimate ways to potentially help minimize that bill - if you know where to look.
Here are three high-impact areas where strategic planning may help minimize your capital gains tax. Try SmartAsset's Financial Advisor Matching Tool Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies typically attract analyst coverage and institutional investment. However, getting in on one of these medical stocks and having it pay off can be like winning the lottery. In an instant, investors could see 3x, 5x, or even 10x returns. Others may never pan out. It's why many investors interested in penny stocks distribute a lump sum across many biotech companies. If it is a numbers game, diversification can be an effective strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but also have the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company that specializes in epigenetics-based tests for early cancer detection. Unlike some penny stocks in this space, Mainz Biomed already has a commercially available product: ColoAlert–the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s leading digital health pioneers. With over 60,000 new colorectal cancer cases annually in Germany, the opportunity is material. Mainz Biomed is also in the early stages of developing a non-invasive, blood-based screening test for pancreatic cancer. The company reported positive topline results in October, but commercial approval is likely years away. The risks are substantial. ColoAlert is not yet available in the United States, and even with early sales in Europe and plans to expand into South America, revenue remains minimal. That's why the company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering to raise capital. For now, that funding helps keep the MYNZ share price above $1 and avoid a delisting notice. The company is racing to generate enough revenue to move the needle. If successful, even a small investment could yield a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive antiviral approach—but it carries significant financial risk that speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new method for treating infectious diseases. NanoViricides’ current pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. But like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to keep programs moving. The company reported limited cash on hand in recent filings, so investors should expect the possibility of future dilution. Still, if one of its candidates advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC stock represents a genuine moonshot in the antiviral space.
| 
